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Abstract: Hepatitis virus infections are the most common cause of liver disease worldwide. 
Sudan is classiﬁ  ed among the countries with high hepatitis B virus seroprevalence. Exposure to 
the virus varied from 47%–78%, with a hepatitis B surface antigen prevalence ranging from 6.8% 
in central Sudan to 26% in southern Sudan. Studies pointed to infection in early childhood in 
southern Sudan while there was a trend of increasing infection rate with increasing age in northern 
Sudan. Hepatitis B virus was the commonest cause of chronic liver disease and hepatocellular 
carcinoma and was the second commonest cause of acute liver failure in the Sudan. Studies 
of hepatitis C virus showed a low seroprevalence of 2.2%–4.8% and there was no association 
with schistosomiasis or with parenteral antischistosomal therapy. Hepatitis E virus was the 
commonest cause of acute hepatitis among pediatric, adult, and displaced populations. Recent 
introduction of screening of blood and blood products for hepatitis B virus and hepatitis C virus 
infections and the introduction of hepatitis B virus vaccine as part of the extended program of 
immunization is expected to reduce the infection rate of these viruses in the Sudan.
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Introduction
Viral hepatitis is a major public health problem affecting several hundred million 
people worldwide. It causes considerable morbidity and mortality from both acute 
infection and chronic sequelae including chronic hepatitis, cirrhosis, and hepatocellular 
carcinoma (HCC). This article aims to summarize most of the studies on viral hepatitis 
in Sudan and try to highlight the burden of the disease and the challenge facing health 
care workers in the country in combating this serious health problem.
Methodology
A comprehensive literature search was performed using electronic databases, primar-
ily Medline. All relevant articles examining the epidemiology of viral hepatitis in 
Sudan since 1981 were carefully analyzed. More than 40 articles were identiﬁ  ed and 
unpublished data was also analyzed when necessary.
Results
Hepatitis B virus
Over two billion people worldwide have evidence of previous or current hepatitis 
B virus (HBV) infection. Three quarters of the world population live in areas with 
high levels of infection; risk factors for infection include blood transfusion, sexual 
intercourse, intravenous drug abuse, vertical and horizontal transmission of the virus. 
Sudan is classiﬁ  ed among countries with a high hepatitis B surface antigen (HBsAg) 
endemicity of more than 8%.1 Exposure to HBV infection ranges from 47%2 to 78%3 
with a hepatitis B surface antigen (HBsAg) seroprevalence ranging from as low as 
6.8%2 in central Sudan to as high as 26%4 in southern Sudan. Identiﬁ  ed risk factors 
for HBV infection in Sudan include living in southern Sudan, parenteral antischisto-
somal therapy,2 sexual promiscuity,3 and scariﬁ  cation4 which is a common ritual in Clinical and Experimental Gastroenterology 2008:1 10
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southern Sudan. There was no association with schistosomal 
infection or blood transfusion2,5 These rates are comparable 
to some African countries where seroprevalence of HBsAg 
was reported at rates of 15.6% in Burundi,6 14% in Central 
African Republic,7 and 10% in Uganda.6 Lower rates were 
however found in other countries such as Tanzania (4.4%),8 
Nigeria (4.98%),9 and Ethiopia (7%).10 Seroprevalence of 
HBsAg among asymptomatic blood donors ranged from 
12.3%11 in southern Sudan to 17.5%12 in central Sudan. 
These studies were carried out in the eighties and nineties 
when screening of blood and blood products was only done 
in a few blood banks in the capital, Khartoum. In 2002, a 
national program for screening blood and blood products 
for HBV and HCV infection was introduced throughout the 
whole country.
A high seroprevalence of HBsAg was detected in 
patients with liver cirrhosis ranging from 31%–61%13,14 and 
similar carrier rates of 43%–60%14,15 were found in patients 
with HCC, indicating that HBV infection is perhaps the 
commonest risk factor for developing HCC besides hepatitis 
C virus (HCV) infection at a rate of 11%.15 Peanut butter, 
a rich source of Aﬂ  atoxin B1 has also been identiﬁ  ed as a 
strong risk factor for HCC in western Sudan; this was well 
documented in a study by Omer and colleagues where 80% 
of cases in a case control study were attributed to a combined 
effect of HBV infection and Aﬂ  atoxin exposure.16 HBV was 
also the second commonest cause of acute liver failure in 
Sudanese subjects at a rate of 22%, seronegative hepatitis 
being the commonest cause at 38%, other causes included 
severe Plasmodium falciparum malaria, hepatitis E virus 
(HEV) and idiosyncratic drug reactions.17 Common risk 
factors for acute liver failure worldwide include paracetamol 
over dose, idiosyncratic drug reactions, HBV infection, and 
seronegative hepatitis.18 Among patients with end-stage renal 
disease undergoing hemodialysis, studies have revealed an 
HBsAg seroprevalence of 7.6%.19 Currently all patients 
planned for hemodialysis who are negative for HBV antibod-
ies are vaccinated prior to undergoing hemodialysis.
Age pattern of HBV infection
Age pattern of exposure to HBV infection differed between 
various geographic locations in Sudan; this was noted in a 
study on the prevalence of HBV exposure in soldiers from 
ﬁ  ve urban locations in Sudan. In soldiers from northern 
Sudan, exposure to HBV infection increased from 47.5% in 
those 20 years of age to 80% in those 39 years of age, 
in contrast , HBV infection was not found to increase after 
the age of 20 years among soldiers raised in the south Sudan 
as 94% of soldiers under the age of 20 years had serologic 
evidence of HBV infection pointing to infection in childhood 
in south Sudan while there was a trend of increasing infection 
rate with increasing age in north Sudan.3
HBV infection in children 
and pregnant ladies
A recent study in Khartoum state on pregnant women showed 
an HBsAg carrier rate of 5.6% with a very low prevalence 
of HCV infection of 0.6%.20 An earlier study in the Gezira 
state in central Sudan showed that 70% of HBsAg positive 
women of child bearing age were also HBeAg-positive,21 an 
important risk factor for vertical transmission of the infection. 
Mother to child transmission of HBV infection was studied 
in Juba, southern Sudan on eighty eight mother and child 
pairs. In nine HBsAg positive mothers, ﬁ  ve of their children 
were infected (55.5%), where as in seventy-nine HBsAg-
negative mothers only nine children were HBsAg-positive 
(11.4%), again pointing towards infection in early childhood 
in southern Sudan. It was however difﬁ  cult to conclude that 
the infection was vertical in these cases as the mean age of 
children studied was 15.5 months.22
Hepatitis D virus
The few studies on HBV infection which conducted Hepa-
titis D virus seroprevalence, found this to be between 9% 
in eastern Sudan23 and 27.8% in central Sudan 21. Studies 
from neighboring Uganda demonstrated seroprevalence 
of anti-D antibodies in up to 30.6% of those who are 
HBsAg-positive.6
Hepatitis C virus
Hepatitis C virus (HCV) is a major cause of end stage liver 
disease in many parts of the world. One hundred and seventy 
million people are estimated to be infected worldwide.24 
Studies on the epidemiology of HCV have suggested that the 
Nile delta region of Egypt has one of the highest prevalence 
rates of HCV infection in the world with seroprevalence 
rates approaching 20% in villagers over the age of 30 years.25 
This was largely attributed to infection with schistosomia-
sis26 and to mass treatment with parenteral antishistosomal 
therapy.27 The few studies on HCV infection in Sudan 
demonstrated a low seroprevalence ranging from 2.2% in 
the Gezira state,28 an area endemic with schistosomiasis 
to 4.8% in patients with schistosomal periportal ﬁ  broses. 
Genotype 4 was the commonest isolated genotype.29 No 
association was found between HCV infection and schis-
tosomiasis or with parenteral antischistosomal therapy.28,29 Clinical and Experimental Gastroenterology 2008:1 11
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Similar HCV seroprevalence was noted in other African 
countries such Ethiopia (2%),30 Central African Republic 
(5%),7 and Libya (7.9%).31 Genotype 4 was also the com-
monest genotype isolated in Cameron,32 Nigeria,33 Egypt,34 
and the Central African Republic.35
Prevalence of HCV infection amongst asymptomatic 
blood donors was found to be 4.4% (Alfadil, Unpublished 
data), currently screening of blood and blood products for 
HCV infection is carried out in most blood banks round the 
country.
The difference between the low seroprevalence of HCV 
infection between Sudan and neighboring Egypt which has 
one of the highest HCV seroprevalence worldwide, may 
be due to the fact that parenteral antishistosomal therapy 
was only offered to those over the age of 12 years in Sudan 
whereas in Egypt it was offered to those over the age of 
6 years, equipment sterilization was more strictly observed 
in Sudan due to low volume of patients treated per ses-
sion when compared to Egypt,27,28 other factors thought 
to contribute to the high seroprevalence in Egypt include 
intravenous drug abuse36 and interfamilial transmission 
between parents and children.37 The highest prevalence 
of HCV infection in Sudan was noted in patients with end 
stage renal disease on regular hemodialysis with a serop-
revalence of 23.7%.19 Major risk factors for infection were 
longer duration of dialysis, dialysis in multiple centers, and 
an age over 30 years.
HBV/HCV and human immunodeﬁ  ciency 
virus co-infection
The only study on HBV and human immunodeﬁ  ciency 
virus (HIV) co-infection was carried out in 1987 on 593 
subjects who practiced high risk behavior, including 
sexual promiscuity. Although the study showed a high 
prevalence of HBV markers (80%), none of the subjects 
was HIV-positive.38 There are as yet no published studies 
on HCV/HIV co-infection. Recent studies from neighbor-
ing African countries reported HBV/HIV co-infection in 
6% of a studied population in Kenya,39 9.2% in Nigeria,40 
and 20.4% in Malawi.41 HCV/HIV co-infection was found 
in 1% in Kenya,39 5.8% in Nigeria,30 and 5% in Malawi.41 
With the spread of HIV infection in the African continent, 
urgent studies are needed in Sudan to assess the current 
prevalence of HBV/HCV/HIV co-infection specially as the 
components of the most common antiretroviral drug therapy 
used in Africa can cause hepatic problems, and lamivudine-
resistant HBV is known to emerge after HBV monotherapy 
in co-infected patients.
Enterically transmitted viruses
It is thought that more than 50% of hepatitis cases occurring 
in developing countries are unrelated to hepatitis A virus 
(HAV) or HBV infection, and a high proportion of these 
cases appear to be enterically transmitted.42 Studies on 
patients with acute hepatitis during the ﬂ  oods of 1988 in 
Khartoum demonstrated that infection was mainly due HEV 
(58%) with low incidence of HAV infection at (5.45%).43 
Another study amongst children with acute hepatitis in 
Khartoum state concluded that HEV was also the common-
est cause of acute clinical hepatitis among that pediatric 
population with HEV infection at 59%, HAV at 33.3%, 
and HBV at 2.6%.44 The largest documented outbreak of 
HEV infection in displaced populations was reported from 
Mornay camp in western Darfur in 2004, when, out of a total 
population of 78,800 people, 2621 were infected with HEV, 
with an attack rate of 3.3% and an overall case-fatality rate 
of 1.7%. Death was highest amongst pregnant women with 
a mortality rate of 31%. The most important risk factor for 
HEV infection was drinking chlorinated surface water. It 
was thought that although the levels of free chlorine residual 
were sufﬁ  cient to reduce fecal coliform load in tap water 
it may not have been enough to inactivate HEV.45,46 This 
outbreak highlights the importance of further laboratory 
studies on inactivation of HEV. Currently HEV is thought 
to be the commonest cause of symptomatic hepatitis in 
both adults and children. As both these viral infections are 
spread via oral – fecal routes, public health measures, such 
as provision of clean water and adequate disposal of sewage 
should be taken.
Viral hemorrhagic fevers
These are a group of illnesses resulting from infection with 
one of several viral families; these include Rift Valley fever, 
yellow fever, and the Ebola virus. Patients commonly present 
with hepatitis among other clinical manifestations. Recently 
an outbreak of Rift Valley fever occurred in the Gezira state 
of central Sudan in November 2007, with over 436 human 
cases reported including 161 deaths, a mortality rate of 37%.47 
Similar outbreaks caused by Ebola virus and yellow fever 
were reported from Sudan in the past.48,49
Conclusion
HBV infection is a major cause of chronic liver disease, 
acute liver failure and HCC in Sudan. Introduction of blood 
and blood products screening for HBV and HCV in all blood 
banks in the country and the inclusion of HBV vaccination 
as part of the extended program of immunization are two Clinical and Experimental Gastroenterology 2008:1 12
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major achievements in the battle against viral hepatitis in 
this country. This is expected to reduce the carrier pool and 
eventually reduce infection rates in both adults and children 
in the coming few years.
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